Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in Canaccord Genuity’s 43rd Annual Growth Conference in Boston.

Event: Canaccord Genuity’s 43rd Annual Growth Conference Date: Wednesday, August 9, 2023 Time: 8:30 – 8:55 am ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc. Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor Contact: David K. Erickson Vice President, Investor Relations Tel: 949-966-1798 Email: david.erickson@evolus.com

Media Contact: Email: media@evolus.com

Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more Evolus Charts.
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more Evolus Charts.